Investments Plan 2026
BIASCA, Switzerland • January 13th, 2026 • HAS Healthcare Advanced Synthesis SA Group announces strategic investment plan to strengthen leadership in CDMO and ADC manufacturing. Download the Press Release
New Sustainability Report
LUGANO, Switzerland • September 4th, 2025 • At Cerbios-Pharma SA, we are fully committed to integrating sustainable practices into every aspect of our operations, recognizing our responsibility towards the environment and the communities we serve. In line with this ongoing commitment, we are proud to publish our latest Sustainability Report, detailing our key efforts in…
HAS Healthcare Advanced Synthesis completes the acquisition of Cerbios
LUGANO, Switzerland • May 7th, 2025 • HAS Healthcare Advanced Synthesis SA completes the acquisition of Cerbios-Pharma SA to establish a top-tier global group in the CDMO industry, backed by 65 Equity Partners. Download the Press Release
HAS acquires Cerbios-Pharma SA
LUGANO, Switzerland • March 31th, 2025 • Today we are proud to announce that Cerbios-Pharma SA, Switzerland and HAS Advanced Synthesis SA, Switzerland (HAS), are joining their forces. Download the Press Release
Cerbios-Pharma S.A. Boosts Production Capabilities for HPAPIs and ADCs
LUGANO, Switzerland • February 28th, 2025 • Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibody-drug conjugates (ADCs). The inauguration was conducted in the presence of Christian Suà, CEO of…
Cerbios-Pharma Commits to Sustainability with New Solar Panel Installation in Lugano
LUGANO, Switzerland • April 8th, 2024 • Cerbios-Pharma SA is proud to announce the completion of a photovoltaic power plant at its Lugano site. This new milestone marks a significant step forward in the Company’s commitment to environmental protection and sustainability, further to last year’s implementation of a new solvent collection and separation process which…
HPAPI and ADC payload manufacturing capacity expansion
LUGANO, Switzerland • May 10th, 2023 • During our long standing 45 years history in the pharmaceutical industry, as Cerbios-Pharma, we have always invested in expanding our capabilities and in the last years more and more resources were addressed to support our customers with innovative CDMO services for HPAPIs and ADCs. Today, we are pleased…
SF68® IBSoft (under development)
Indications: indicated for the dietary management of colonopathies with altered trophism of the intestinal mucosa
Regulatory status: to be defined
SF68® Slipido
Indications: for maintenance of normal blood levels of cholesterol and normal metabolism of homocysteine
Regulatory status: Food Supplement (EU & Switzerland)
SF68® Skin Active
Indications: for maintenance of normal skin
Regulatory status: Food Supplement (EU & Switzerland)
